Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded by The Goldman Sachs Group to “Strong-Buy” Rating

The Goldman Sachs Group upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO) to a strong-buy rating in a research note published on Tuesday,Zacks reports.

A number of other analysts have also recently weighed in on LTGO. Wall Street Zen upgraded shares of Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th. Jefferies Financial Group began coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They set a “buy” rating and a $50.00 price target on the stock. Guggenheim started coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price target for the company. Finally, Leerink Partners assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price target on the stock. Four analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Latigo Biotherapeutics presently has an average rating of “Strong Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Stock Performance

Shares of NASDAQ LTGO opened at $22.26 on Tuesday. Latigo Biotherapeutics has a 12-month low of $17.22 and a 12-month high of $25.93.

Insider Transactions at Latigo Biotherapeutics

In related news, Director James B. Tananbaum acquired 140,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the director owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the insider directly owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Trending Headlines about Latigo Biotherapeutics

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Multiple analyst upgrades: Leerink Partners, Jefferies Financial Group, Guggenheim, and Goldman Sachs each upgraded Latigo to “strong-buy.” The broad agreement among analysts may improve investor confidence and increase demand for LTGO shares.
• Positive Sentiment: Goldman Sachs initiates Buy rating: Analyst Salveen Richter cited Latigo’s differentiated non-opioid pain platform and Nav1.8 pipeline, along with the potential for significant peak sales. The thesis suggests investors see commercial opportunity in Latigo’s approach to pain treatment without opioids. Salveen Richter Initiates Buy on Latigo for Differentiated Non-Opioid Pain Platform and Nav1.8 Pipeline with Strong Peak Sales Potential
• Neutral Sentiment: Investor focus remains on the pipeline: Latigo’s valuation and future stock performance will likely depend on clinical progress, regulatory milestones, and whether its Nav1.8 candidates can demonstrate meaningful efficacy and safety in pain indications.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.